First conference, in collaboration with the American Journal of Endocannabinoid Medicine, will happen November 15th in NYC, featuring world-leading global experts in science, healthcare and law
NEW YORK, Sept. 12, 2019 /PRNewswire/ — Over 120 million Americans have tried CBD, with the numbers increasing on a daily basis, and two-thirds of US states, and 22 countries, have legalized marijuana for medical purposes. The innovation within cannabis and cannabinoids are at their infancy, but there are 333 known medication interactions and the endocannabinoid system is connected throughout the brain and body’s major organs. Whether you’re prepared for it or not, there is a new cannabis reality in the world.
While usage and innovation is growing astronomically, clear understanding of the science that supports cannabinoid and cannabis products, the potential drug interactions, labelling, quality control and perhaps most urgently, liability, is not. In fact, only 13% of medical schools offer any instructional material on the human endocannabinoid system (ECS), the biological system discovered in the 1990s, and very little science-based training exists at all. The surge in cannabis use presents profound impact on the healthcare community, covering the entire spectrum from tremendous opportunity to serious risk and liability, with providers and prescribers facing very real urgency to get an understanding of the science and law.
Havas ECS, founded earlier this year by Havas Health & You, is filling this gap starting this fall. Today, Havas ECS announced “Medical Cannabis; The science. The research. The risks.” a full spectrum education program for the medical and legal communities, starting with a conference in collaboration with the American Journal of Endocannabinoid Medicine (AJEM), November 15th of this year in New York. While the conference is relevant to any attendee across the health and legal spectrums, anyone who wants to learn about the science and liability surrounding cannabis would benefit. Featured speakers are the world’s leading industry and medical experts, including Phillipe Lucas, VP Patient Research and Access at Tilray, Dr. Margaret Haney, Professor of Neurobiology (in Psychiatry) Columbia University Medical Center, Lauren Rudick, Attorney at Hiller PC New York, Member of the National Cannabis Bar Association, Dr. Jahan Marcu, Editor in Chief of the AJEM and many more. The first conference kicks off a series of education events and curriculums, with more dates and programs to be announced throughout 2020.
The first conference will cover a range of key categories, including the high science of the endocannabinoid system, drug and disease interactions and risks, uses, and delivery systems. A completely unique part of this conference is what Havas ECS calls “the trial the world is waiting for”, a mock trial focused on a real-life scenario including a doctor, patient, a cannabis product, a fatal accident and two trial lawyers. The patient in the trial will be played by former NFL star, Marvin Washington, who is an advocate for ex-players dealing with the effects of concussions and pain management. The medical audience will be the jury, tasked with deciding where the liability lies.
https://finance.yahoo.com/news/havas-ecs-announces-medical-education-131000133.html?guccounter=1
